United States - English - NLM (National Library of Medicine)

viiv healthcare company - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - abacavir 600 mg - epzicom, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (hiv‑1) infection. epzicom is contraindicated in patients: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to epzicom during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for abacavir or lamivudine compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital defects program (macdp) reference population (see data) . the apr uses the macdp as the u.s. reference population for birth defects in the general population. the macdp evaluates women and infants from a limited geographic area and does not include outcomes for births that occurred at less than 20 weeks’ gestation. the rate of miscarri

United States - English - NLM (National Library of Medicine)

viiv healthcare company - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95), zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s) - abacavir 300 mg - trizivir is indicated in combination with other antiretrovirals or alone for the treatment of human immunodeficiency virus type 1 (hiv‑1) infection. limitations of use: trizivir is contraindicated in patients: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to trizivir during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for abacavir, lamivudine, or zidovudine compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital defects program (macdp) reference population (see data) . the apr uses the macdp as the u.s. reference population for birth defects in the general population. the macdp evaluates women and infants from a limited geographic area and does not include outcomes for births that occurred at less than 20 w

United States - English - NLM (National Library of Medicine)

viiv healthcare company - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs) - abacavir 300 mg - ziagen tablets and oral solution, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus (hiv-1) infection. ziagen is contraindicated in patients: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ziagen during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for abacavir compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital defects program (macdp) reference population (see data) . the apr uses the macdp as the u.s. reference population for birth defects in the general population. the macdp evaluates women and infants from a limited geographic area and does not include outcomes for births that occurred at less than 20 weeks’ gestation. the rate of misca

United States - English - NLM (National Library of Medicine)

viiv healthcare company - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), dolutegravir sodium (unii: 1q1v9v5wyq) (dolutegravir - unii:dko1w9h7m1), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - abacavir 600 mg - triumeq and triumeq pd are indicated for the treatment of hiv-1 infection in adults and in pediatric patients aged at least 3 months and weighing at least 6 kg. limitations of use: triumeq and triumeq pd alone are not recommended in patients with resistance‑associated integrase substitutions or clinically suspected integrase strand transfer inhibitor (insti) resistance because the dose of dolutegravir in triumeq and triumeq pd is insufficient in these subpopulations. see full prescribing information for tivicay (dolutegravir). triumeq and triumeq pd are contraindicated in patients: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to triumeq during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1‑800‑258‑4263. risk summary data from an ongoing birth outcome surveillance study has identified an increased risk of neural tube defects when dolutegravir, a componen

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - cabotegravir, quantity: 30 mg (equivalent: cabotegravir sodium, qty mg) - tablet, film coated - excipient ingredients: titanium dioxide; magnesium stearate; hypromellose; lactose monohydrate; microcrystalline cellulose; sodium starch glycollate type a; macrogol 3350 - vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults who are virologically suppressed (hiv-1 rna <50 copies/ml) and have no known or suspected resistance to either cabotegravir or rilpivirine (see sections 4.2 dose and method of administration and 5.1 pharmacodynamic properties, clinical trials) for: ? oral lead in to assess tolerability of cabotegravir prior to administration of cabotegravir prolonged-release suspension for injection plus rilpivirine prolonged-release suspension for injection. ? oral therapy for adults who will miss planned dosing with cabotegravir prolonged-release suspension for injection.

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - fostemsavir trometamol, quantity: 724.56 mg - tablet, modified release - excipient ingredients: colloidal anhydrous silica; hyprolose; hypromellose; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - rukobia is indicated in combination with other antiretroviral agents for the treatment of heavily treatment-experienced adults with multidrug-resistant human immunodeficiency virus-1 (hiv-1) infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen due to resistance, intolerance or safety considerations (see section 5.1 pharmacodynamic properties, clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - dolutegravir sodium, quantity: 5.26 mg (equivalent: dolutegravir, qty 5 mg) - tablet, dispersible - excipient ingredients: sodium starch glycollate; mannitol; microcrystalline cellulose; povidone; purified water; silicified microcrystalline cellulose; crospovidone; calcium sulfate dihydrate; sucralose; sodium stearylfumarate; hypromellose; macrogol 400; titanium dioxide; flavour - tivicay and tivicay pd are indicated for the treatment of human immunodeficiency virus (hiv) infection in combination with other antiretroviral agents in adults and children of at least 4 weeks in age or older and weighing 3 kg or more (see section 4.4 special warnings and precautions for use, dual regimens).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viiv healthcare uk ltd - fosamprenavir calcium - tablet - 700mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viiv healthcare uk ltd - fosamprenavir calcium - oral suspension - 50mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viiv healthcare uk ltd - lamivudine - tablet - 300mg